Sartorius AG
SRT
Rang in Aktien
#1196
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of... Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Aktienkurs
$247.31
Marktkapitalisierung
$19.26B
Veränderung (1 Tag)
0.97%
Veränderung (1 Jahr)
930.90%
Land
DE
Handel Sartorius AG (SRT)
Kategorie
Healthcare
P/B-Verhältnis für Sartorius AG (SRT)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Sartorius AG beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Sartorius AG von 2026 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 8.1997 | - |
US
|
|
| 1.7417 | - |
FR
|
|
| - | - |
JP
|
|
| 2.1258 | - |
US
|
|
| - | - |
CH
|
